Previous 10 | Next 10 |
Organon Canada launches Ontruzant®, a biosimilar of the reference biologic Herceptin®, providing patients in Canada with certain breast and gastric cancers with an additional therapeutic option at a lower cost Canada NewsWire KIRKLAND, QC , Nov. 14,...
Organon ( NYSE: OGN ) had declared $0.28/share quarterly dividend , in line with previous. Payable Dec. 15; for shareholders of record Nov. 14; ex-div Nov. 10. See OGN Dividend Scorecard, Yield Chart, & Dividend Growth. For further details see: Organo...
Organon Canada launches Aybintio®, a biosimilar of the reference biologic Avastin®, providing a new option at a reduced cost for Canadians living with certain aggressive forms of cancer Canada NewsWire KIRKLAND, QC , Nov. 7, 2022 /CNW/ - Organon...
The following slide deck was published by Organon & Co. in conjunction with their 2022 Q3 earnings call. For further details see: Organon & Co. 2022 Q3 - Results - Earnings Call Presentation
Organon & Co. (OGN) Q3 2022 Earnings Conference Call November 03, 2022 8:30 AM ET Company Participants Jennifer Halchak – Vice President, Investor Relations Kevin Ali – Chief Executive Officer Matt Walsh – Chief Financial Officer Sand...
Merck ( MRK ) spinoff Organon & Co. ( NYSE: OGN ) rose after its Q3 2021 financials topped Street forecasts on Thursday, even as the company reported a decline in revenue for the second consecutive quarter. Revenue for the quarter fell ~4% YoY on a GAAP basis to ...
Organon press release ( NYSE: OGN ): Q3 Non-GAAP EPS of $1.32 beats by $0.22 . Revenue of $1.54B (-3.8% Y/Y) beats by $20M . Full year 2022 financial guidance ranges updated: Revenue range narrowed to $6.1 billion to $6.2 billion and reflects persisting for...
Third quarter 2022 revenues of $1,537 million Third quarter diluted earnings per share from continuing operations of $0.89 and non-GAAP adjusted diluted earnings per share from continuing operations of $1.32 Both reported and non-GAAP adjusted diluted earnings per share includ...
Summary Organon is a spinout of Merck's Established Brands, Women's Health and Biosimilars divisions. The company began life saddled with ~$9.4bn of debt versus annual revenue generation of ~$6.5bn. The share price is down nearly 30% over the past 12 months as currency headwin...
Summary Merck has seen very strong growth so far this year, even if we strip out the pandemic related contribution. Strong growth has resulted in an uptick in the valuation multiple, all while multiples in the market at large are compressing amidst rising rates. I still like t...
News, Short Squeeze, Breakout and More Instantly...
VANCOUVER, BC / ACCESSWIRE / July 24, 2024 / (TSXV:OGN)(OTCQX:OGNRF) Orogen Royalties Inc. ("Orogen" or the "Company") is pleased to announce updates for its partner funded exploration stage projects and royalties. Highlights Estimated 30,000 metres of drilling in seven planned or comp...
Company estimates $15 million of milestone expense in the second quarter Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, will release its second quarter 2024 financial results on August 6, 2024, prior to the company’s webcast and conference...
2024-06-08 06:50:00 ET Not all dividend stocks are equal. Some are safer than others. Some have much higher dividend yields than others. When a stock offers both advantages, it's usually a keeper. Three Motley Fool contributors have found stocks with mouthwatering dividends that you...